文献速递白血病

吉妥珠单抗奥唑米星治疗NPM1突变急性髓系白血病:AMLSG 09-09前瞻性随机III期研究早期结果

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.
PubMed 文献 · J Clin Oncol · 2019-12-18

PURPOSE: High CD33 expression in acute myeloid leukemia (AML) with mutated NPM1 provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity.…

要点

  • GO联合强化化疗未显著改善NPM1突变AML的无事件生存。
  • GO臂诱导期早期死亡率10.3%,标准臂5.7%,差异接近统计学意义。
  • 达CR/CRi患者中GO显著降低复发累积发生率,不增加死亡累积发生率。

核心结论

  • 试验未达到无事件生存的早期主要终点,主要归因于GO臂较高的早期死亡率。
  • 在诱导治疗后达CR/CRi的患者中,GO臂较标准臂复发显著减少。

研究设计与样本

  • 随机分配至标准臂(n=296)或GO臂(n=292),诱导方案为去甲氧柔红霉素、阿糖胞苷、依托泊苷和全反式维甲酸±GO。
  • 早期主要终点为无事件生存,于患者入组完成后6个月评估。

主要发现

  • 亚组分析显示GO对女性、≤70岁和FLT3内部串联重复阴性患者在无事件生存和复发累积发生率方面有显著获益。

临床怎么用

  • 在NPM1突变AML中,GO联合强化化疗未显著改善无事件生存,且需关注诱导期早期死亡风险。
  • 对诱导后达CR/CRi的患者,GO可显著降低复发累积发生率,尤其女性、≤70岁和FLT3-ITD阴性患者可能获益。

局限性

  • 早期主要终点评估时随访时间较短,无事件生存差异未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: High CD33 expression in acute myeloid leukemia (AML) with mutated NPM1 provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity. We conducted a randomized trial to evaluate GO in combination with intensive induction and consolidation therapy in NPM1-mutated AML. PATIENTS AND METHODS: Between May 2010 and September 2017, patients ≥ 18 years old and considered eligible for intensive therapy were randomly assigned up front for induction therapy with idarubicin, cytarabine, etoposide, and all-trans-retinoic acid with or without GO. The early (P = .02) primary end point of event-free survival (EFS) was evaluated 6 months after completion of patient recruitment. RESULTS: Five hundred eighty-eight patients were randomly assigned (standard arm, n = 296; GO arm, n = 292). EFS in the GO arm was not significantly different compared with that in the standard arm (hazard ratio, 0.83; 95% CI, 0.65 to 1.04; P = .10). The early death rate during induction therapy was 10.3% in the GO arm and 5.7% in the standard arm (P = .05). Causes of death in both arms were mainly infections. The cumulative incidence of relapse (CIR) in patients achieving a complete remission (CR) or CR with incomplete hematologic recovery (CRi) was significantly reduced in the GO arm compared with the standard arm (P = .005), with no difference in the cumulative incidence of death (P = .80). Subgroup analysis revealed a significant beneficial effect of GO in female, younger (≤ 70 years), and FLT3 internal tandem duplication-negative patients with respect to EFS and CIR. CONCLUSION: The trial did not meet its early primary end point of EFS, mainly as a result of a higher early death rate in the GO arm. However, in patients achieving CR/CRi after induction therapy, significantly fewer relapses occurred in the GO compared with the standard arm.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Schlenk RF, Paschka P, Krzykalla J, et al. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2019. PMID: 31851556. doi:10.1200/JCO.19.01406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。